Summary
The Liver Study Group of Hokkaido analyzed a total of 57 patients with non-resectable primary liver cancers, which were treated by intra-arterial adriamicin infusion chemotherapy combined with lipiodol and/or the Gelform embolization of the hepatic arteries. Of the ten patients considered clinical responders, three complete response patients and seven partial response cases were obtained. The overall response rate was 17.5%. The median survival period at each clinical stage was as follows: stage I: 13.0 months, stage II: 16.0 months, stage III: 11.5 months and stage IV: 4.7 months. The common side-effects of this treatment were nausea, vomiting and anorexia. Hematological toxicities were also found, but there was no patient who suffered from severe complications.
Similar content being viewed by others
References
Konno T, Maeda H, Iwai K, et al. (1983) Effect of arterial administration of high molecular weight anticancer agent smancs with lipid lymphographic agent on hepatoma. A preliminary report. Eur J Cancer Clin Oncol 19: 1065
Liver Cancer Study Group of Japan (1984) Primary liver cancer in Japan. Cancer 54: 1747
Nagasue N, Yukaya H, Hamada T, et al. (1984) The natural history of hepatocellular carcinoma — a study of 100 untreated cases. Cancer 54: 146
Okuda K, Obata H, Nakajima Y, et al. (1984) Prognosis of primary hepatocellular carcinoma. Hepatology 4: 3S–6S
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kusano, M., Mito, M., Nakanishi, M. et al. Cooperative study on arterial regional chemotherapy for primary liver cancer in Hokkaido. Cancer Chemother. Pharmacol. 23 (Suppl 1), S17–S20 (1989). https://doi.org/10.1007/BF00647232
Issue Date:
DOI: https://doi.org/10.1007/BF00647232